Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma

Oncology Reports

Volumn 37, Issue 6, 2017, Pages 3405-3414

  Zhao, Tiesuo ^a   Jia, Huijie ^a   Cheng, Qian ^b   Xiao, Yali ^a   Li, Minming ^a   Ren, Wenjing ^a   Li, Chen ^a   Feng, Yuchen ^a   Feng, Zhiwei ^a   Wang, Hui ^a   Zheng, Junnian ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor immune response; HCC; Nifuroxazide; STAT3; TCL loaded DC

Indexed keywords

NIFUROXAZIDE; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; HYDROXYBENZOIC ACID DERIVATIVE; NITROFURAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INVASION; CELL LYSATE; CELL MIGRATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR CELL LYSATE; ANIMAL; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; HYDROXYBENZOATES; LIVER NEOPLASMS; MICE; NITROFURANS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019622453     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5629     Document Type: Article

References (44)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Llovet JM: Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 7: 431-441, 2004.
3. Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150: 835-853, 2016.
4. Zhao F, Korangy F and Greten TF: Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis 30: 477-482, 2012.
5. Harding JJ, El Dika I and Abou-Alfa GK: Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer 122: 367-377, 2016.
6. Steinman RM and Cohn ZA: Pillars Article: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.1973. 137: 1142-1162. J Immunol 178: 5-25, 2007.
7. Sun K, Wang L and Zhang Y: Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Cell Mol Immunol 3: 197-203, 2006.
8. Ge C, Xing Y, Wang Q, Xiao W, Lu Y, Hu X, Gao Z, Xu M, Ma Y, Cao R, et al: Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432. Int Immunopharmacol 11: 2200-2207, 2011.
9. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR and Chen MF: Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J Immunother 28: 496-504, 2005.
10. Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, et al: A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 113: 1666-1676, 2015.
11. Sun X, Zhang J, Wang L and Tian Z: Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213, 2008.
12. Sui Q, Zhang J, Sun X, Zhang C, Han Q and Tian Z: NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol 193: 2016-2023, 2014.
13. Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, et al: Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases. Mol Cancer Ther 15: 2334-2343, 2016.
14. Hillmer EJ, Zhang H, Li HS and Watowich SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev 31: 1-15, 2016.
15. Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51, 2007.
16. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC and Frank DA: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112: 5095-5102, 2008.
17. Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X, Li Y, Jie H, Liu C, Xiong Y, et al: Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis 6: E1701, 2015.
18. Chang WT, Chen HM, Yin SY, Chen YH, Wen CC, Wei WC, Lai P, Wang CH and Yang NS: Specific Dioscorea phytoextracts enhance potency of TCL-loaded DC-based cancer vaccines. Evid Based Complement Alternat Med 2013: 932040, 2013.
19. Yin SY, Wang CY and Yang NS: Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage. Exp Cell Res 317: 2210-2221, 2011.
20. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM and Gabrilovich DI: Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 175: 4338-4346, 2005.
21. Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol 21: 35-43, 2011.
22. Kalinski P: Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 10: 526-535, 2009.
23. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
24. Cacalano NA: Regulation of natural killer cell function by STAT3. Front Immunol 7: 128, 2016.
25. Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C and Desir GV: Renalase expression by melanoma and tumor-associated macrophages promotes tumor growth through a STAT3-mediated mechanism. Cancer Res 76: 3884-3894, 2016.
26. Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A and Yu H: STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer Immunol Res 3: 864-870, 2015.
27. Ghoshal S, Fuchs BC and Tanabe KK: STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surg Nutr 5: 201-203, 2016.
28. Zheng X, Xu M, Yao B, Wang C, Jia Y and Liu Q: IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Cell Signal 28: 1314-1324, 2016.
29. Tang Q, Jiang J and Liu J: CCR5 blockade suppresses melanoma development through inhibition of IL-6-Stat3 pathway via upregulation of SOCS3. Inflammation 38: 2049-2056, 2015.
30. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M and Kokhaei P: Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol 257: 23-31, 2009.
31. Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, Kim YK, Chung SY, Choi SJ, Kim HJ, et al: The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res 33: 665-670, 2009.
32. Jia H, Li Y, Zhao T, Li X, Hu J, Yin D, Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immunother 61: 1977-1987, 2012.
33. McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, et al: I L-21 e nhances n atural k iller c ell r esponse t o cetuximab-coated pancreatic tumor cells. Clin Cancer Res 23: 489-502, 2017.
34. Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Gajewski TF, et al: NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells. J Immunol 197: 953-961, 2016.
35. Kozlowska AK, Tseng HC, Kaur K, Topchyan P, Inagaki A, Bui VT, Kasahara N, Cacalano N and Jewett A: Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother 65: 1085-1097, 2016.
36. Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, et al: YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep 4: 6031, 2014.
37. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
38. Dong W, Xian Y, Yuan W, Huifeng Z, Tao W, Zhiqiang L, Shan F, Ya F, Hongli W, Jinghuan W, et al: Catalpol stimulates VEGF production via the JAK2/STAT3 pathway to improve angiogenesis in rats' stroke model. J Ethnopharmacol 191: 169-179, 2016.
39. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A and Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65: 5054-5062, 2005.
40. Hsieh FC, Cheng G and Lin J: Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335: 292-299, 2005.
41. Miklossy G, Hilliard TS and Turkson J: Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12: 611-629, 2013.
42. Walker SR, Xiang M and Frank DA: Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 382: 616-621, 2014.
43. Cheung TH, Chung TK, Lo KW, Yu MY, Krajewski S, Reed JC and Wong YF: Apotosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Gynecol Oncol 86: 14-18, 2002.
44. Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568, 2007.